IL119029A0 - Long-acting drugs and pharamaceutical compositions comprising them - Google Patents
Long-acting drugs and pharamaceutical compositions comprising themInfo
- Publication number
- IL119029A0 IL119029A0 IL11902996A IL11902996A IL119029A0 IL 119029 A0 IL119029 A0 IL 119029A0 IL 11902996 A IL11902996 A IL 11902996A IL 11902996 A IL11902996 A IL 11902996A IL 119029 A0 IL119029 A0 IL 119029A0
- Authority
- IL
- Israel
- Prior art keywords
- peptide
- hirudin
- conjugates
- long
- acting drugs
- Prior art date
Links
- 239000003509 long acting drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 108010007267 Hirudins Proteins 0.000 abstract 2
- 102000007625 Hirudins Human genes 0.000 abstract 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract 2
- 229940006607 hirudin Drugs 0.000 abstract 2
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-07 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
| CZ99369A CZ36999A3 (cs) | 1996-08-07 | 1997-08-05 | Dlouho působící farmaceutika a farmaceutické sloučeniny, které obsahují tyto látky |
| DK97933828T DK1019089T3 (da) | 1996-08-07 | 1997-08-05 | Langtidsvirkende lægemidler og farmaceutiske præparater der omfatter disse |
| CN97197122A CN1227501A (zh) | 1996-08-07 | 1997-08-05 | 长效药物及含有该长效药物的药物组合物 |
| EP97933828A EP1019089B1 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| PCT/IL1997/000265 WO1998005361A2 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| AT97933828T ATE308998T1 (de) | 1996-08-07 | 1997-08-05 | Langwirkende arzneistoffe und diese enthaltende arzneimittel |
| ES97933828T ES2252787T3 (es) | 1996-08-07 | 1997-08-05 | Principios activos de efecto prolongado y composciones farmaceuticas que los incluyen. |
| NZ333845A NZ333845A (en) | 1996-08-07 | 1997-08-05 | Long-acting Fmoc-substituted and Fm-substituted pro-drugs |
| DE69734607T DE69734607T2 (de) | 1996-08-07 | 1997-08-05 | Langwirkende arzneistoffe und diese enthaltende arzneimittel |
| JP50777098A JP4416184B2 (ja) | 1996-08-07 | 1997-08-05 | 長期作用型薬物およびこれらを含む薬剤組成物 |
| CA002261835A CA2261835C (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| US09/242,026 US6504005B1 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| HU0000809A HUP0000809A2 (hu) | 1996-08-07 | 1997-08-05 | Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények |
| BR9711045A BR9711045A (pt) | 1996-08-07 | 1997-08-05 | Drogas de atua-Æo prolongada e composi-{es farmac-uticas compreendendo as mesmas |
| IL12827497A IL128274A0 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| AU37060/97A AU725468B2 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| KR1019997000941A KR20000029806A (ko) | 1996-08-07 | 1997-08-05 | 장기간-작용의약및이를포함한약제학적조성물 |
| IL128274A IL128274A (en) | 1996-08-07 | 1999-01-28 | Long-acting drugs and pharmaceutical compositions comprising them |
| NO990518A NO990518L (no) | 1996-08-07 | 1999-02-04 | Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse |
| US10/408,262 US20040092443A1 (en) | 1996-08-06 | 2003-04-08 | Long-acting exendins and exendin agonists |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-07 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL119029A0 true IL119029A0 (en) | 1996-11-14 |
Family
ID=11069166
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-06 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
| IL12827497A IL128274A0 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| IL128274A IL128274A (en) | 1996-08-07 | 1999-01-28 | Long-acting drugs and pharmaceutical compositions comprising them |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12827497A IL128274A0 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
| IL128274A IL128274A (en) | 1996-08-07 | 1999-01-28 | Long-acting drugs and pharmaceutical compositions comprising them |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6504005B1 (pt) |
| EP (1) | EP1019089B1 (pt) |
| JP (1) | JP4416184B2 (pt) |
| KR (1) | KR20000029806A (pt) |
| CN (1) | CN1227501A (pt) |
| AT (1) | ATE308998T1 (pt) |
| AU (1) | AU725468B2 (pt) |
| BR (1) | BR9711045A (pt) |
| CA (1) | CA2261835C (pt) |
| CZ (1) | CZ36999A3 (pt) |
| DE (1) | DE69734607T2 (pt) |
| DK (1) | DK1019089T3 (pt) |
| ES (1) | ES2252787T3 (pt) |
| HU (1) | HUP0000809A2 (pt) |
| IL (3) | IL119029A0 (pt) |
| NO (1) | NO990518L (pt) |
| NZ (1) | NZ333845A (pt) |
| WO (1) | WO1998005361A2 (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139400A0 (en) * | 2000-11-01 | 2001-11-25 | Yeda Res & Dev | Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| AU3938402A (en) * | 2000-12-13 | 2002-06-24 | Lilly Co Eli | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| PL211116B1 (pl) | 2001-10-19 | 2012-04-30 | Idexx Lab | Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| JP4033382B2 (ja) * | 2002-04-08 | 2008-01-16 | 久光製薬株式会社 | インスリン投与装置 |
| EP2259068B1 (en) * | 2003-01-16 | 2013-08-14 | caprotec bioanalytics GmbH | Capture compounds and methods for analyzing the proteome |
| PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| WO2004091601A1 (fr) * | 2003-04-17 | 2004-10-28 | Jallal Messadek | Formulations orales flottantes pour la liberation controlee de la betaine |
| PL2107069T3 (pl) | 2003-08-05 | 2013-06-28 | Novo Nordisk As | Nowe pochodne insuliny |
| BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| MX2007013486A (es) * | 2005-04-27 | 2008-03-14 | Jallal Messadek | Combinaciones de insulinas. |
| DK1969004T3 (da) | 2005-12-28 | 2011-11-28 | Novo Nordisk As | Insulinsammensætninger og metode til at lave en sammensætning |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
| EP2910569B1 (en) | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| JP5765813B2 (ja) * | 2008-09-19 | 2015-08-19 | ウェルズ ファーゴ バンク ナショナル アソシエイション | 治療用ペプチドのポリマーコンジュゲート |
| JP5775820B2 (ja) * | 2008-10-21 | 2015-09-09 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法 |
| AU2009309623B9 (en) | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| EP2403537A1 (en) | 2009-03-05 | 2012-01-11 | Ascendis Pharma A/S | Interferon alpha carrier prodrugs |
| WO2011013128A2 (en) | 2009-07-31 | 2011-02-03 | Yeda Research And Development Co. Ltd. | Vectors for delivery of neurotherapeutics to the central nervous system |
| US8754190B2 (en) * | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
| RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
| EP2490378B1 (en) | 2011-02-18 | 2014-07-09 | NTT DoCoMo, Inc. | Apparatus and method for determining a control unit using feasibility requests and feasibility responses |
| AU2012261869B2 (en) | 2011-06-02 | 2017-01-05 | Opko Biologics Ltd. | Long-acting GLP-1/Glucagon receptor agonists |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| JP6199956B2 (ja) | 2012-04-11 | 2017-09-20 | ノヴォ ノルディスク アー／エス | インスリン製剤 |
| SG11201408054RA (en) | 2012-06-04 | 2015-01-29 | Opko Biolog Ltd | Pegylated oxm variants |
| US20150111820A1 (en) | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| JP6690062B2 (ja) | 2016-12-16 | 2020-04-28 | ノヴォ ノルディスク アー／エス | インスリン含有医薬組成物 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR20210126088A (ko) | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | 지속성 glp-2 유사체 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU906340D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US6313094B1 (en) * | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| JPH0687887A (ja) * | 1992-08-19 | 1994-03-29 | Upjohn Co:The | ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤 |
| US5631222A (en) | 1993-06-25 | 1997-05-20 | Kyowa Hakko Kogyo Co., Ltd. | Endothelin-antagonizing peptide |
| US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| WO1995021622A1 (en) | 1994-02-09 | 1995-08-17 | Brigham & Women's Hospital | Gel-forming polypeptide derivatives |
| DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| AU5377296A (en) * | 1995-03-30 | 1996-10-16 | Southpac Trust International, Inc. | Self-erecting container which is collapsible to be substanti ally flat |
| US5688992A (en) | 1995-03-31 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof |
| US5846934A (en) * | 1996-02-20 | 1998-12-08 | American Cyanamid Company | Pure somatostatin antagonist and methods of use thereof |
| US6057297A (en) * | 1996-08-06 | 2000-05-02 | Polifarma S.P.A. | Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof |
-
1996
- 1996-08-07 IL IL11902996A patent/IL119029A0/xx unknown
-
1997
- 1997-08-05 US US09/242,026 patent/US6504005B1/en not_active Expired - Lifetime
- 1997-08-05 NZ NZ333845A patent/NZ333845A/xx unknown
- 1997-08-05 ES ES97933828T patent/ES2252787T3/es not_active Expired - Lifetime
- 1997-08-05 AU AU37060/97A patent/AU725468B2/en not_active Ceased
- 1997-08-05 DK DK97933828T patent/DK1019089T3/da active
- 1997-08-05 WO PCT/IL1997/000265 patent/WO1998005361A2/en active IP Right Grant
- 1997-08-05 IL IL12827497A patent/IL128274A0/xx active IP Right Grant
- 1997-08-05 JP JP50777098A patent/JP4416184B2/ja not_active Expired - Lifetime
- 1997-08-05 AT AT97933828T patent/ATE308998T1/de active
- 1997-08-05 HU HU0000809A patent/HUP0000809A2/hu unknown
- 1997-08-05 BR BR9711045A patent/BR9711045A/pt not_active IP Right Cessation
- 1997-08-05 CZ CZ99369A patent/CZ36999A3/cs unknown
- 1997-08-05 EP EP97933828A patent/EP1019089B1/en not_active Expired - Lifetime
- 1997-08-05 DE DE69734607T patent/DE69734607T2/de not_active Expired - Lifetime
- 1997-08-05 KR KR1019997000941A patent/KR20000029806A/ko not_active Application Discontinuation
- 1997-08-05 CN CN97197122A patent/CN1227501A/zh active Pending
- 1997-08-05 CA CA002261835A patent/CA2261835C/en not_active Expired - Lifetime
-
1999
- 1999-01-28 IL IL128274A patent/IL128274A/en not_active IP Right Cessation
- 1999-02-04 NO NO990518A patent/NO990518L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998005361A3 (en) | 1998-06-18 |
| WO1998005361A2 (en) | 1998-02-12 |
| HUP0000809A2 (hu) | 2000-11-28 |
| CZ36999A3 (cs) | 1999-07-14 |
| AU725468B2 (en) | 2000-10-12 |
| CN1227501A (zh) | 1999-09-01 |
| DK1019089T3 (da) | 2006-03-13 |
| EP1019089A2 (en) | 2000-07-19 |
| ATE308998T1 (de) | 2005-11-15 |
| US6504005B1 (en) | 2003-01-07 |
| KR20000029806A (ko) | 2000-05-25 |
| NZ333845A (en) | 2000-09-29 |
| IL128274A (en) | 2006-08-01 |
| AU3706097A (en) | 1998-02-25 |
| NO990518L (no) | 1999-04-06 |
| BR9711045A (pt) | 1999-08-17 |
| NO990518D0 (no) | 1999-02-04 |
| ES2252787T3 (es) | 2006-05-16 |
| DE69734607D1 (de) | 2005-12-15 |
| CA2261835C (en) | 2008-07-29 |
| EP1019089B1 (en) | 2005-11-09 |
| JP2000515542A (ja) | 2000-11-21 |
| DE69734607T2 (de) | 2006-08-03 |
| JP4416184B2 (ja) | 2010-02-17 |
| CA2261835A1 (en) | 1998-02-12 |
| IL128274A0 (en) | 1999-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL119029A0 (en) | Long-acting drugs and pharamaceutical compositions comprising them | |
| IL135148A0 (en) | A polysaccharide conjugate and pharmaceutical compositions containing the same | |
| EP0701448A4 (en) | AMPLIFICATION OF THE VITAMIN B 12 ADSORPTION SYSTEM? BY POLYMERS | |
| AU4162400A (en) | Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii | |
| IL113812A0 (en) | Copolymer-1, pharmaceutical compositions containing it and its use | |
| HK1029124A1 (en) | Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them. | |
| EP1705190A3 (en) | Peptide derivatives | |
| WO1995013297A3 (en) | Improved immunogenic compositions against human gastrin 17 | |
| PH31059A (en) | Pharmaceutical compositions comprising cyclosporins. | |
| EP0695171A1 (en) | LONOSPHERES CONTAINING GONADOTROPHIN | |
| EP1003526A4 (en) | COVALENT-TIED N, O-CARBOXYMETHYLCHITOSAN AND ITS USE | |
| WO2000023094A3 (en) | Methods of inhibiting platelet activation and recruitment | |
| MY104520A (en) | Polymyxin conjugates. | |
| CA2114313A1 (en) | Bpc peptides, their preparation and use | |
| AU7683296A (en) | Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them | |
| EP1006126A3 (en) | Osteogenic peptides | |
| IL121969A0 (en) | 10,13,15-trioxatricyclo[9.2.1.1.9.6]-pentadecanone derivatives their preparation and pharmaceutical compositions containing them | |
| AU3870195A (en) | A novel family of protease inhibitors, and other biologic active substances | |
| IL139604A (en) | Fibrinogen-beta chain derived peptide, compositions comprising same and use thereof | |
| EP0786256A3 (en) | Obesity protein formulations | |
| ZA9710254B (en) | LH-RH peptide analogues, their uses and pharmaceutical composition containing them. | |
| AU7209594A (en) | Anti-inflammatory peptides | |
| AU6760294A (en) | Immunotherapeutic peptides derived from toxic shock syndrome toxin-1, antibodies thereto, their uses in pharmaceutical compositions and diagnosis | |
| IL100853A0 (en) | Msh peptide derivatives,their preparation and pharmaceutical compositions comprising them | |
| CA2344470A1 (en) | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues |